

9 June 2016

Buy

Private & Commercial Finance Group*

Strong results and banking licence in sight

Current price
31p


Target price
42p (from 30p)

Market cap
£49.7m

PCFG has delivered adj. PBT of £3.5m in the 12 months to end March 2016, in line with our upgraded forecast following the trading update. With the change of year-end and the banking licence application submitted last month, we have moved the basis of our forecasts to pro forma 12 month periods to September 2016 and are no longer treating banking costs as exceptional. We have also moved the basis of our target price to a ratio of 0.6x our forecast FY2016 loans portfolio equal to 42p per share (from 30p). Buy rating retained.

Price performance

| | Stock | All-Share |
|-----------|-------|-----------|
| 1 month: | 0.8% | 2.5% |
| 3 month: | 52.4% | 1.3% |
| 12 month: | 89.4% | -7.1% |



Last results
Interims, 9 Jun 16

Next results
Finals, Dec 16

Next event
Trading update, Oct 16

Reuters / BBG
PCF.L / PCF.LN

Index
FTSE AIM

Priced at close
8 June 2016

Analysts
Robert Sanders
020 7601 6111
robert.sanders@stockdalesecurities.com

Key forecasts

| Year to | Sales | PBT | EPS | EPS | DPS | Dividend | P/E | EV/EBITDA | ROE |
|---------|-------|-----|-----|----------|-----|----------|------|-----------|------|
| Sep | £m | £m | p | growth % | p | yield % | x | x | % |
| 2015A# | 48.2 | 2.8 | 1.3 | 62.2 | 0.0 | 0.0 | 23.2 | 2.1 | 10.7 |
| 2016E# | 54.5 | 3.6 | 1.6 | 21.2 | 0.1 | 0.3 | 19.1 | 5.2 | 11.0 |
| 2017E | 62.7 | 3.7 | 1.4 | -11.4 | 0.2 | 0.6 | 21.6 | 5.7 | 7.3 |
| 2018E | 78.4 | 6.0 | 2.3 | 55.7 | 0.3 | 1.0 | 13.9 | 4.5 | 10.7 |

Source: Stockdale, # estimates for the 12 months to 2015 and 2016 as year-end changed to September from March

Results to end March 2016 continue to show strong progress

Following the change of year end to September to bring it in line with its 72% shareholder, Bermuda Commercial Bank (BCB), PCFG will be reporting an 18-month period to September 2016. The results for the 12 months to March 2016 show a 67% increase in adj. PBT to £3.5m on a portfolio of £112m (up 12%). The portfolio quality is demonstrated by the record low level of impairments at 1.1% (1.6% a year ago).

Exceeding key targets

An indication of how strong the business has performed is that both the key targets of a 2.0 % return on average assets and a 10% return on equity were significantly beaten, with the former hitting 3.1% and the latter 13.9% for the reported period. This compares to 2.2% and 10.2% respectively in the prior year and has led to PCFG increasing the targets for the shorter-term to 2.5% and 12.5%.

Banking licence will open up much larger addressable market

Although PCFG has committed facilities to continue to grow its business in order to achieve its medium-term target of a £250m loans portfolio, it needs to access cheaper capital. To do this PCFG has been progressing through the banking licence application process over the last 12-18 months, which culminated in the application being submitted on 13 May 2016. With the regulatory authorities expected to respond within six months we no longer treat the costs associated with becoming a bank as "exceptional" and thus our adjusted PBT and reported PBT are the same. We forecast £1m of mobilisation costs in FY2017 but little benefit to the portfolio, but then a significant increase in both portfolio size and PBT in FY2018.

Changed basis of valuation has led to increased 42p target price

From September 2014, we had based our target price on an earnings-based multiple and, while this has been sensible given the strong earnings progression over the last two years, we now believe a target price based on the market capitalisation as a percentage of receivables better reflects the growth opportunity. Our 42p target price (previously 30p) represents 0.6x the £120m portfolio we forecast for September 2016. With our forecast of significant portfolio growth in the next two years, there is scope to increase our target price further in due course. We view the intention to re-introduce a dividend as an additional attraction for investors.

Overview

Company activities

Private & Commercial Finance Group (PCFG) specialises in the provision of finance through two divisions, Consumer Finance (providing finance to consumers mainly for used vehicles) and Business Finance (providing finance to SMEs for vehicles, plant and equipment). PCFG has c.12,000 agreements in place and a total loan portfolio of c.£112m. From its offices in London, management operates an efficient and scalable business model, with scope for enhanced returns through the expansion of its receivables portfolio. With 45 employees, the company has short lines of communication that enable fast decision-making. This is bolstered further by its internet-based proposals system, eQuote. Focused on prime customers, PCFG generates attractive yields and has low bad debt charges. With a diverse customer base, no single customer accounts for more than 0.6% of the portfolio.

Key issues on which investors must take a view

At the heart of PCFG's business model is the ability to generate a margin by borrowing from providers of finance at one rate and then lending this on to consumers and SMEs at a higher rate. A key issue in recent years had been the sourcing of new finance as banks cut lending. In the last year, PCFG has negotiated new and improved funding agreements and currently has committed headroom of over £25m, so we are confident that this position has improved. As a collateral-backed lender of good-quality liquid assets with new initiatives for growth, we believe PCFG is well-placed to grow its receivables portfolio and profitability. A further catalyst to this will be achieved when PCFG gets its banking licence which is progressing following the submission of the application in May 2016.

Likely direction of consensus revisions

PCFG has an experienced and dedicated management team and is now in a stronger position given its improved funding and initiatives for growth. Given the progress with the banking licence we have adjusted our PBT forecasts to reflect the costs of this and the benefits to come in due course. While we expect a much increased portfolio size following the attainment of the deposit-taking licence, it will be FY2018 before we forecast earnings progression given the costs involved ahead of mobilisation.

Valuation and reason behind target price

From September 2014 we based our target price on an earnings-based multiple rather than an NAV-based one. While this has been sensible given the strong earnings progression over the last two years we are now moving to a target price based on the market capitalisation as a percentage of receivables. As a consequence we now have a 42p target price which represents 0.6x the £120m portfolio we forecast for September 2016. Obviously, with our forecast of significant portfolio growth in the next two years there is scope to increase our target price further in due course. We view the intention to re-introduce a dividend as an additional attraction for investors.

Risks to our view

We believe that PCFG is well placed to deliver a progressive rise in its receivables portfolio now it has secured additional funding and the banking licence is progressing. A significant increase in competitive pressures or economic upheaval could pose a risk to our positive view. Any problems or delays in the banking licence process could impact management's ability to grow the portfolio and/or the return on average assets in the medium-term.

Assumptions

We now include the costs of becoming a bank and the benefits of future deposits in our forecasts

As previously announced, PCFG is moving its year end to September to coincide with the year-end of its 72% shareholder BCB and will therefore be reporting on an 18-month period to end September 2016. In Table 1 below we show our breakdown of the last three reported six-monthly periods and our forecast for the six months to end September 2016 to try to show the underlying profit progress that PCFG has been making. We have then created pro forma results for the 12 months to end September 2015 and 2016. PCFG has previously broken out central costs in the periods up to September 2015 but has now restated these results by allocating them to the two divisions. In addition, now that the banking licence application has been submitted, we are including the costs associated with becoming a bank (which we have previously shown as exceptional and added back to get our adjusted PBT - these amounted to £224k in the 12 months to March 2016), as part of the operating expenses. This means that our adjusted and reported PBT will be the same for our pro forma 12 months to end September 2016 and future years. As Table 1 shows the full benefit of taking deposits will initially start to come through in FY2018.

Table 1: Assumptions

| Year end September (£'000) | 2015H1A# | 2015H2A# | 2015A# | 2016H1A# | 2016H2E | 2016E# | 2017E | 2018E |
|--------------------------------------|---------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Consumer Finance | | | | | | | | |
| Revenues | 12,580 | 13,104 | 25,684 | 13,835 | 14,417 | 28,252 | 32,490 | 40,613 |
| % increase | 7.7 | 12.1 | 9.9 | 10.0 | 10.0 | 10.0 | 15.0 | 25.0 |
| PBT | 751 | 980 | 1,731 | 1,367 | 1,402 | 2,769 | 3,184 | 4,061 |
| PBT margin | 6.0 | 7.5 | 6.7 | 9.9 | 9.7 | 9.8 | 9.8 | 10.0 |
| Business Finance | | | | | | | | |
| Revenues | 10,719 | 11,836 | 22,555 | 12,487 | 13,790 | 26,277 | 30,218 | 37,773 |
| % increase | 8.8 | 14.9 | 11.9 | 16.5 | 16.5 | 16.5 | 15.0 | 25.0 |
| PBT | 500 | 612 | 1,112 | 557 | 636 | 1,193 | 1,511 | 3,211 |
| PBT margin | 4.7 | 5.2 | 4.9 | 4.5 | 4.6 | 4.5 | 5.0 | 8.5 |
| Total | | | | | | | | |
| Revenue | 23,299 | 24,940 | 48,239 | 26,322 | 28,207 | 54,529 | 62,708 | 78,385 |
| % increase | 8.2 | 13.4 | 10.8 | 13.0 | 13.1 | 13.0 | 15.0 | 25.0 |
| Segmental PBT | 1,251 | 1,592 | 2,843 | 1,924 | 2,038 | 3,962 | 4,695 | 7,272 |
| PBT margin | 5.4 | 6.4 | 5.9 | 7.3 | 7.2 | 7.3 | 7.5 | 9.3 |
| Central Costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank | | (67) | (67) | (157) | (230) | (387) | (1,000) | (1,300) |
| Adjusted PBT | 1,251 | 1,659 | 2,910 | 1,767 | 1,808 | 3,575 | 3,695 | 5,972 |
| PBT margin | 5.4 | 6.7 | 6.0 | 6.7 | 6.4 | 6.6 | 5.9 | 7.6 |
| Reported PBT | 1,251 | 1,525 | 2,776 | 1,767 | 1,808 | 3,575 | 3,695 | 5,972 |
| End year portfolio size | | | | | | | | |
| | 99,829 | 108,000 | 108,000 | 112,000 | 119,732 | 119,732 | 139,969 | 198,475 |
| <i>% margin on average portfolio</i> | 2.5 | 2.8 | 2.7 | 3.1 | 3.0 | 3.1 | 2.8 | 3.5 |

Source: Stockdale # we have shown our estimates for the 6 and 12 month periods to end September 2015 and 2016 as company has changed its year-end to September from March. It will thus report on an 18 month period to September 2016.

Banking Licence

Table 2 below shows the timetable of events since PCFG considered applying for a deposit-taking licence at the beginning of 2015 and the various stages of the application process it has gone through up to submitting its application on 13 May 2016. There is now a period of up to six months before PCFG receives a response from the regulatory authorities, hence our expectation that this will occur around the time the final results for the 18 month period to September 2016 are released in December 2016.

Table 2: Timeline of banking application/licence

| Date | |
|-------------|--|
| 2015 | |
| Q1 | Banking licence project kicked off with system selection, Business plan production and exploratory conversations with the regulator |
| Q2 | Business plan submitted for feedback sessions |
| Jul | First of three meetings with regulators occurred |
| 2016 | |
| Jan | Final feedback session meeting occurred |
| Mar | PRA/FCA invited PCFG to first challenge sessions to discuss the Capital and liquidity regulatory reviews (termed the Technical Challenge Session) |
| Apr | RA/FCA invited PCFG to second challenge sessions to discuss the Regulatory Business Plan |
| May | PRA/FCA invited PCFG to submitted application and this was duly submitted on 13 May 2016 |
| Dec | Expected response from PRA/FCA Upon application approval the mobilisation of the business plan, including governance, systems, risks, compliance and control to take between 6 – 9 months |
| 2017 | |
| Jan | Stockdale expects PCFG will raise £10m of regulatory capital as part of the mobilisation process |
| Q3 | First deposits will be taken |

Source: Company data, Stockdale estimates

We have forecast that £10m of regulatory capital will be raised issuing 30 million shares at 33.5p by end January 2017

On the assumption that the banking licence application is approved PCFG has indicated it will take 6-9 months to mobilise the business plan. One of the initial elements of this will be to raise sufficient regulatory capital. We believe that this will range from a minimum of £5m up to £20m. In order to create our forecasts for FY2017 and FY2018 we have assumed that £10m of regulatory capital will be required. We have forecast that this will be achieved by issuing 30 million shares at 33.5p by end January 2017 so there will a weighted average of an additional 20 million shares in FY2017 and the full 30 million in FY2018. While there will be an additional £1m costs in the banking mobilisation in FY2017 there will be no real portfolio benefit as the first deposits are only likely to occur in the latter part of the financial year, hence our forecast of relatively flat group PBT for FY2017.

Sensitivity analysis

While the full benefit of the cheaper cost of capital will be felt in years after FY2018 Table 2 below shows a sensitivity analysis on a range of return on average assets from the target of 2.5% up to 4.0% on an average portfolio size of £150m to the targeted £250m. This analysis becomes applicable in FY2018 as our £4.7m PBT forecast would be a 3.5% return on average assets on an average portfolio size of £170m. Obviously, if PCFG can beat the 3.5% RoAA forecast and/or the portfolio grows ahead of our forecast then there is upside potential to our FY2018 forecast.

Table 3: PBT sensitivity analysis to portfolio size and return on average assets (£m)

| Average portfolio size (£m) | Return on average assets | | | | |
|-----------------------------|--------------------------|------|------|------------|------|
| | 2.5% | 2.7% | 3.0% | 3.5% | 4.0% |
| 150 | 3.8 | 4.1 | 4.5 | 5.3 | 6.0 |
| 170 | 4.3 | 4.6 | 5.1 | 6.0 | 6.8 |
| 200 | 5.0 | 5.4 | 6.0 | 7.0 | 8.0 |
| 225 | 5.6 | 6.1 | 6.8 | 7.9 | 9.0 |
| 250 | 6.3 | 6.8 | 7.5 | 8.8 | 10.0 |

Source: Stockdale estimates

Asset finance market

Asset finance as an alternative source of funding has been a strong growth market

Asset finance as an alternative source of funding has achieved exceptional growth through 2014 and 2015 and PCFG expects strong growth to continue beyond 2016 hence its banking application to access more of this market. The Finance & Leasing Association (FLA) reported £29bn of new business in the asset finance market in 2015, up 13% on the previous years. The growth was broad-based across many asset finance sectors – the largest of which were cars (up 11% to £8.9bn), commercial vehicles (up 14% to £6.9bn) and plant & machinery (up 7% to £5.8bn).

PCFG's share of the SME Asset & Vehicle Finance and Consumer Motor Finance markets is currently less than 0.5%. This is largely as a result of the group's current treasury model and pricing structure, which means it is unable to compete on a significant number of transactions. Indeed, PCFG believes that its current pricing structure prevents it from accessing 80% of each market. This section of the market consists of customers with a better credit profile than currently seen, who by definition expect to pay a lower interest rate.

PCFG will be able to address this barrier issue as a consequence of the banking licence and a new treasury model and, therefore, be able to compete in grades higher up the credit spectrum. Indeed, there should be opportunity to grow both the amount of new business and, thus, market share in each of its divisions. Furthermore, the ability to offer lower rates should ensure that PCFG has better customer retention as currently it loses those customers which improve their credit profile sufficiently to access cheaper finance.

Valuation

We view the 0.6x ratio of market cap to receivables portfolio implied by our 42p target price as conservative in the light of some of the recent multiples paid

Our new target price is derived from assuming a ratio of 0.6x the £120m receivables portfolio that we forecast for end-September 2017. We then divide the implied £71.5m market capitalisation by the current 170.4m fully-diluted shares in issue to derive 42p per share. We view this multiple as realistic given Non-Standard Finance PLC has been consolidating in this market with the purchase of Every Day Loans from Secure Trust for which it paid £235m (£107m cash, repaying £108m of debt and £20m of NSF shares) implying a 2.3x multiple relative to the last-reported £102m receivables. Its earlier purchase of the Home Credit business, Loansathome4u, from S&U for £82.5m implied a 2.4x multiple of the January 2015 loan book of £34.6m. Provident Financial Group bought Money Barn in August 2014 for £120m, implying a multiple of 0.9x the £133m receivables at that time, it has subsequently grown this to a £243m portfolio in sub-prime car finance.

Table 4: Ratio of market cap to receivables

| Company | Mkt Cap (£m) | Last reported receivables portfolio (£m) | Ratio (x) |
|----------------------|--------------|--|------------|
| PCFG | 49.7 | 112 | 0.5 |
| 1pm | 37 | 47.9 | 0.8 |
| Manx Financial Group | 9.2 | 101.4 | 0.1 |
| Provident Financial | 4313 | 2060 | 2.1 |
| S&U | 268 | 160 | 1.7 |
| Secure Trust Bank | 500 | 1074.9 | 0.5 |

Source: Company data, Stockdale estimates

The intention to return to the dividend list is positive in our view

Table 5 below shows the valuation metrics (where available) of the above companies. We view the intention to have a progressive dividend policy in place from September 2016 as an added attraction to investors.

Table 5: Peer group analysis

| Calendarised data to September year end | Price (p) | Market cap (£m) | P/E | | EV/EBITDA | | Yield (net) (%) | |
|---|-------------|-----------------|-------------|-------------|------------|------------|-----------------|------------|
| | | | 2016E# | 2017E | 2016E# | 2017E | 2016E# | 2017E |
| PCFG | 31.3 | 49.7 | 19.1 | 21.6 | 5.2 | 4.7 | 0.3 | 0.6 |
| 1pm | 69.5 | 36.5 | na | na | na | na | na | na |
| Manx Financial Group | 9.3 | 9.4 | na | na | na | na | na | na |
| Provident Financial | 2878.0 | 4,249.1 | 18.2 | na | na | na | 4.2 | na |
| S&U | 2350.0 | 280.8 | 14.9 | 15.0 | na | na | 3.0 | 3.2 |
| Secure Trust Bank | 2630.0 | 478.4 | 12.4 | 11.6 | na | na | 3.1 | 3.3 |
| Linear average | | | 16.1 | 16.1 | 5.2 | 4.7 | 2.7 | 2.4 |

Source: Stockdale estimates # we have shown our estimates for the 12 month period to end September 2016 as company has changed its year-end to September from March. It will thus report on an 18 month period to September 2016. Factset. Priced at close: 7 June 2016

Financials

Table 6: Income statement

| Year end September (£ 000) | 2015A# | 2016E'# | 2017E | 2018E |
|-----------------------------------|--------------|--------------|--------------|--------------|
| Revenues | 48,239 | 54,529 | 62,708 | 78,385 |
| <i>% increase</i> | 13.1 | 13.0 | 15.0 | 25.0 |
| Cost of sales | -33,961 | -38,170 | -43,896 | -54,870 |
| <i>% group revenues</i> | 70.4 | 70.0 | 70.0 | 70.0 |
| <i>% increase</i> | 12.8 | 12.4 | 15.0 | 25.0 |
| Gross profit | 14,278 | 16,359 | 18,812 | 23,516 |
| <i>% group revenues</i> | 29.6 | 30.0 | 30.0 | 30.0 |
| Operating expenses | -6,598 | -7,331 | -8,847 | -9,705 |
| <i>% group revenues</i> | 13.7 | 13.4 | 14.1 | 12.4 |
| Operating profit (pre-x) | 7,680 | 9,028 | 9,966 | 13,810 |
| <i>% group revenues</i> | 15.9 | 16.6 | 15.9 | 17.6 |
| Exceptional/bank costs | -67 | -387 | -1,000 | -1,300 |
| Operating profit | 7,680 | 9,028 | 9,966 | 13,810 |
| <i>% group revenues</i> | 15.9 | 16.6 | 15.9 | 17.6 |
| Net interest inc/(chrg) | -4,904 | -5,453 | -6,271 | -7,839 |
| Other financial items | - | - | - | - |
| Net financial items | -4,904 | -5,453 | -6,271 | -7,839 |
| PBT | 2,776 | 3,575 | 3,695 | 5,972 |
| <i>% group revenues</i> | 5.8 | 6.6 | 5.9 | 7.6 |
| PBT (pre-x) | 2,776 | 3,575 | 3,695 | 5,972 |
| Tax | -485 | -792 | -939 | -1,454 |
| <i>% PBT</i> | 17.5 | 22.2 | 25.4 | 24.4 |
| <i>% Pre-exceptional PBT</i> | 20.0 | 20.0 | 20.0 | 20.0 |
| Total tax charge | -485 | -792 | -939 | -1,454 |
| Net profit | 2,291 | 2,782 | 2,756 | 4,518 |
| <i>% group revenues</i> | 4.7 | 5.1 | 4.4 | 5.8 |
| Net profit (pre-x) | 2,291 | 2,782 | 2,756 | 4,518 |
| <i>% group revenues</i> | 4.7 | 5.1 | 4.4 | 5.8 |
| <i>RoE</i> | 10.7 | 11.0 | 7.3 | 10.7 |
| Fully-diluted shares in issue (m) | 170.0 | 170.4 | 190.4 | 200.4 |
| EPS (pre-x) (p) | 1.3 | 1.6 | 1.4 | 2.3 |
| <i>% increase</i> | 62.2 | 21.2 | -11.4 | 55.7 |

Source: Stockdale # we have shown our estimates for the 12 month periods to end September 2015 and 2016 as company has changed its year-end to September from March. It will thus report on an 18 month period to September 2016.

Table 7: Cash flow

| Year end September (£ 000) | 2015A | 2016E | 2017E | 2018E |
|-------------------------------------|-----------|-----------|------------|-----------|
| PBT | 2,776 | 3,575 | 3,695 | 5,972 |
| Depreciation reversal | 28 | 20 | 70 | 70 |
| Amortisation | 181 | 145 | 445 | 445 |
| Amortisation -other | 136 | 33 | 33 | 33 |
| Non-recurring items | - | - | - | - |
| Change in core working capital | -11,046 | -623 | -3,412 | -8,723 |
| (Profit)/loss on sale of FA | - | - | - | - |
| Cash tax (paid)/received | -277 | -792 | -939 | -1,454 |
| Share based payments | 4 | - | - | - |
| Other items | -18 | - | - | - |
| Gross cash flow (as stated) | -8,216 | 2,357 | -109 | -3,657 |
| Net interest (paid)/received | - | - | - | - |
| Gross cash flow | -8,216 | 2,357 | -109 | -3,657 |
| Gross TFA capex | -84 | -20 | -500 | -20 |
| Proceeds from TFA disposals | 33 | - | - | - |
| Net capex on TFA | -51 | -20 | -500 | -20 |
| Intangible fixed assets expenditure | -72 | -175 | -1,500 | -175 |
| Acquisitions of businesses | - | - | - | - |
| Hire purchases advances | - | - | - | - |
| Issue of ordinary shares | 8,500 | 1,000 | 10,000 | - |
| Issue of CULS | - | - | - | - |
| Debt | -8,500 | -3,200 | -7,800 | 4,000 |
| Dividends paid | - | - | - | -190 |
| Balancing item | - | - | - | - |
| CHANGE IN CASH | -8,339 | -38 | 91 | -42 |
| Net cash | 51 | 13 | 105 | 62 |

Source: Stockdale # we have shown our estimates for the 12 month periods to end September 2015 and 2016 as company has changed its year-end to September from March. It will thus report on an 18 month period to September 2016.

| Table 8: Balance sheet | | | | |
|---------------------------------------|----------------|----------------|-----------------|-----------------|
| Year end September (£ 000) | 2015A | 2016E | 2017E | 2018E |
| Assets | | | | |
| Tangible fixed assets | 100 | 100 | 530 | 480 |
| Goodwill/intangibles | 869 | 866 | 1,888 | 1,585 |
| Loans & receivables | 69,079 | 79,500 | 93,703 | 144,874 |
| Deferred tax assets | 1,717 | 1,625 | 1,625 | 1,625 |
| Non-current assets | 71,765 | 82,091 | 97,746 | 148,564 |
| Trade and other receivables (debtors) | 1,043 | 1,179 | 1,356 | 1,695 |
| Loans & receivables | 38,427 | 40,232 | 46,266 | 53,601 |
| Gross cash (and equivalents) | 510 | 472 | 564 | 521 |
| Current assets | 39,980 | 41,883 | 48,186 | 55,818 |
| Total assets | 111,745 | 123,975 | 145,932 | 204,381 |
| Liabilities | | | | |
| Debt LT | -71,069 | -78,591 | -84,831 | -135,156 |
| Non-current liabilities | -71,069 | -78,591 | -84,831 | -135,156 |
| Provisions | - | - | - | - |
| Gross debt (and equivalents) | -459 | -459 | -459 | -459 |
| Trade and other payables (creditors) | -1,654 | -1,870 | -2,150 | -2,688 |
| Interest-bearing loans and borrowings | -17,073 | -17,875 | -20,556 | -23,815 |
| Tax liabilities | - | - | - | - |
| Current liabilities | -19,186 | -20,203 | -23,165 | -26,962 |
| Total liabilities | -90,255 | -98,794 | -107,996 | -162,118 |
| Equity | | | | |
| Share capital | 7,656 | 8,564 | 18,564 | 18,564 |
| Share premium | 7,898 | 7,898 | 7,898 | 7,898 |
| Other reserve | 3,349 | 3,349 | 3,349 | 3,349 |
| Retained earnings | 2,585 | 5,369 | 8,125 | 12,452 |
| Shareholders' funds | 21,488 | 25,180 | 37,936 | 42,263 |
| Minority interests | - | - | - | - |
| Equity capital | 21,490 | 25,180 | 37,936 | 42,263 |

Source: Stockdale # we have shown our estimates for the 12 month periods to end September 2015 and 2016 as company has changed its year-end to September from March. It will thus report on an 18 month period to September 2016.

Explanation of recommendations

Each structure below is based on total shareholder return defined as the absolute rise in share price plus dividend payment over a 12-month period

| Stockdale recommendation structure | | Stockdale recommendation proportions in last quarter | | | |
|------------------------------------|--------------|--|-------|--------------------------------|-------|
| | | All stocks excluding AIM | | Corporate stocks excluding AIM | |
| Buy | +20% or more | Buy | 79.2% | Buy | 94.1% |
| Add | +10% to +20% | Add | 4.2% | Add | 0.0% |
| Neutral | (+/-) 10% | Neutral | 16.7% | Neutral | 5.9% |
| Sell | -10% or more | Sell | 0.0% | Sell | 0.0% |

Source: Stockdale

Stockdale acts as a market maker or liquidity provider for this company.

Stockdale has provided investment banking services to this company within the last 12 months.

The company has seen this research but no material changes have been made as a result.

Unless otherwise stated, the author of this research is the first analyst listed on the front cover of this document. Analysts' remuneration is based on a number of factors, including the overall results of Stockdale Securities Limited ('Stockdale'), to which a contribution is made by investment banking activities. Analysts' remuneration is not based on expressing a specific view or recommendation on an issuer, security or industry.

This research is classified as being a "marketing communication" as defined by the FCA's Handbook. This is principally because analysts at Stockdale are involved in investment banking activities and pitches for new business and consequently this research has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Therefore, the research is not subject to any prohibition on dealing ahead of the dissemination of investment research. Nevertheless, the Firm's Conflict of Interest Management Policy prohibits dealing ahead of research, except in the normal course of market making and to satisfy unsolicited client orders. Please refer to www.stockdalesecurities.com for a summary of our conflict of interest management policy in relation to research. This includes organisational controls (departmental structure, a Chinese wall between corporate finance and other departments, etc), procedures on the supervision and remuneration of analysts, a prohibition on analysts receiving inducements for favourable research, editorial controls and review procedures over research recommendations and a prohibition on analysts undertaking personal account dealings in companies covered by them.

This document has been approved by Stockdale for communication to professional clients (as defined in the FCA Handbook) and to persons who, if they were clients of Stockdale, would be professional clients. Any recommendations contained in this document are intended solely for such persons. This document is not intended for use by persons who are retail clients of Stockdale or, who would if they were clients of Stockdale, be retail clients, who should consult their investment adviser before following any recommendations contained herein. In any event this document should not be regarded by the person to whom it is communicated as a substitute by the recipient of the recipient's own judgement and does not constitute investment advice (as defined in the FCA Handbook) and is not a personal recommendation. This document is based on information obtained from sources which we believe to be reliable; however, it is not guaranteed as to accuracy or completeness by Stockdale, and is not to be construed as a representation by Stockdale. Expressions of opinion herein are subject to change without notice. This document is not and should not be construed as an offer or the solicitation of an offer to buy or sell any securities. Past performance is not necessarily a guide to future performance. The value of the financial instruments referred to in this research may go down as well as up. Stockdale and its associated companies and/or their officers, directors and employees may from time to time purchase, subscribe for, or add to or dispose of any shares or other securities (or interests) discussed herein. Recipients must not pass this research document on to any other person except with the prior written permission of Stockdale. Stockdale is authorised and regulated by The Financial Conduct Authority (Registered Number 114265) and is a member of The London Stock Exchange. Stockdale Bryan Garnier, Bryan Garnier Stockdale and Stockdale are trading names of Stockdale Securities Limited. Registered Office: Beaufort House, 15 St. Botolph Street, London, EC3A 7BB. Registered in England Number: 762818. The Financial Conduct Authority address is 25 The North Colonnade, Canary Wharf, London E14 5HS. Alastair Stewart, Gareth Evans and Mark Henderson have contracts for services with Stockdale to write research.

U.S Disclosures

This research report was prepared by Stockdale Securities Limited. Stockdale and its research analysts are not members of the Financial Industry Regulatory Authority, Inc. As a result, Bryan Garnier Securities LLC is distributing this research in the United States of America on behalf of Stockdale in accordance with SEC Rule 15a-6. Bryan Garnier Securities LLC, a broker-dealer registered with the U.S. Securities and Exchange Commission, has assumed responsibility for this research for purposes of U.S. law. All transactions arising from this research with U.S. Counterparties should be effected by Bryan Garnier Securities LLC unless an exemption exists under SEC Rule 15a6.

| No | Disclosure | Response |
|----|---|----------|
| 1 | At the end of the month immediately preceding the date of publication of this research report (or the end of the second most recent month if the publication date is less than 10 calendar days after the end of the most recent month), does Bryan Garnier Securities LLC or its affiliates beneficially own 1% or more of any class of common equity securities of the subject company(ies)? | NO |
| 2 | Has Bryan Garnier Securities LLC or affiliate: (a) managed or co-managed a public offering of securities for the subject company in the past 12 months, or (b) received compensation for investment banking services from the subject company(ies) in the past 12 months; or (c) expects to receive or intends to seek compensation for investment banking services from the subject company(ies) in the next 3 months? | NO |
| 3 | Was Bryan Garnier Securities LLC making a market in the subject company's securities at the time that the research report was published? | NO |
| 4 | Do all the views expressed in this research report accurately reflect the research analyst's personal views regarding any and all of the subject securities or issuers? | YES |
| 5 | Is any part of analyst compensation was, is or will be, directly or indirectly related to the specific recommendations or views expressed in this research report? | NO |
| 6 | Are there any other actual, material conflicts of interest of the research analyst or member of which the research analyst knows or has reason to know at the time of publication of the research report? | NO |

Stockdale Securities, Beaufort House, 15 St. Botolph Street, London, EC3A 7BB

Email: firstname.surname@stockdalesecurities.com

Research

Head of Research, Insurance & Financials

Joanna Parsons 020 7601 6133

Growth Companies

Robert Sanders 020 7601 6111

Peter Ashworth 020 7601 6112

Property & Support Services

Alastair Stewart 020 7601 6149

Investment Funds (IF)

Saumya Banerjee 020 7601 6629

Oil & Gas

Mark Henderson 020 7601 6100

Technology

Gareth Evans 020 7601 6132

William Bin Xu 020 7601 6129

Executive Chairman

Mark Brown 020 7601 6126

Sales

Fiona Conroy 020 7601 6136

Richard Harris (IF) 020 7601 6107

Matthew Kinhead (IF) 020 7601 6626

Pauline Tribe (IF) 020 7601 6623

Joshua Nimmo 020 7601 6143

Simon Wickham, Head of Sales 020 7601 6141

Steve Yelland 020 7601 6142

Sales Trading

Michael Harrison 020 7601 6611

Trading

Helen Brown 020 7601 6603

Darren Papper (IF) 020 7601 6632

Calum Summers (IF) 020 7601 6631

Managing Director

Andy Crossley 020 7601 6108